Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genotonorm for Growth Retardation in Juvenile Arthritis Extension Study
NCT00174291Phase 3Terminated
- Sponsor
- Pfizer
- Start
- Mar 2002
- Primary completion
- Oct 2011
- Modality
- Hormone, rProtein (Recombinant Protein), Biologic
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of somatropin, sponsored by Pfizer. Primary endpoints: Change From Baseline in Annual Rate of Growth Standard Deviation Score, Change From Baseline in Height Standard Deviation Score and 1 more. Started Mar 2002; status: terminated.
02
Drugs
somatropin
Beyond the preview
Go deeper on NCT00174291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00174291.